Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
ObjectiveThis study aimed to assess the efficacy and safety of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) in patients with locally advanced cervical cancer (LACC) via meta-analysis.MethodsA systematic literature search of MEDLINE, PubMed, Web of Science, EMBASE, and the Cochr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.997030/full |
| _version_ | 1828092669548560384 |
|---|---|
| author | Haonan Liu Xiao Ma Chenyu Sun Meng Wu Zhiyuan Xu Shuang Zhou Nan Yao Suya Liu Xiaobing Qin Zhengxiang Han |
| author_facet | Haonan Liu Xiao Ma Chenyu Sun Meng Wu Zhiyuan Xu Shuang Zhou Nan Yao Suya Liu Xiaobing Qin Zhengxiang Han |
| author_sort | Haonan Liu |
| collection | DOAJ |
| description | ObjectiveThis study aimed to assess the efficacy and safety of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) in patients with locally advanced cervical cancer (LACC) via meta-analysis.MethodsA systematic literature search of MEDLINE, PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials was conducted from January 10, 1966 to May 20, 2022. Randomized controlled trials and observational studies comparing the CCRT alone with CCRT plus ACT were included. The literature search, quality assessment, and data extraction were conducted by two reviewers independently. The primary endpoints were 3-year rates of overall survival (OS) and progression-free survival (PFS). Complete response rate, local recurrence, distant metastasis, and adverse events were secondary outcomes. The hazard ratios (HRs) and relative risk (RR) were pooled.ResultsNine studies with a total of 2732 patients were included in this meta-analysis, including 1411 patients in the CCRT group and 1321 in the CCRT plus ACT group. The HR for 3-year rates of OS and PFS of the CCRT group compared with the CCRT plus ACT group was 0.72 [95%confidence interval (CI) = 0.44–1.17] and 0.78 (95%CI = 0.5–1.75), respectively. No significant differences were observed between the two groups in the complete response rate (RR = 1.06, 95%CI = 0.96–1.16). However, local recurrence and distant metastasis were significantly lower in the CCRT plus ACT group than in the CCRT group (RR = 0.63, 95%CI = 0.44 –0.91 and RR = 0.64, 95%CI = 0.47–0.88). Grade 3–4 acute toxicities were more frequent in the CCRT plus ACT group (RR = 1.73, 95%CI =1.19–2.52).ConclusionAlthough associated with a decreased risk of local recurrence and distant metastasis, ACT did not significantly improve the survival rate and the complete response rate with increasing grade 3–4 acute toxicities in patients with LACC. Thus, this ACT regimen cannot be recommended for patients with LACC.Systematic review registrationhttps://inplasy.com/inplasy-2022-9-0089/, identifier INPLASY202290089. |
| first_indexed | 2024-04-11T06:31:08Z |
| format | Article |
| id | doaj.art-e888d1ec63b64b76981af0f38e3ac9cf |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T06:31:08Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e888d1ec63b64b76981af0f38e3ac9cf2022-12-22T04:40:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.997030997030Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysisHaonan Liu0Xiao Ma1Chenyu Sun2Meng Wu3Zhiyuan Xu4Shuang Zhou5Nan Yao6Suya Liu7Xiaobing Qin8Zhengxiang Han9Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, IL, United StatesDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Emergency, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaDepartment of Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, ChinaObjectiveThis study aimed to assess the efficacy and safety of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) in patients with locally advanced cervical cancer (LACC) via meta-analysis.MethodsA systematic literature search of MEDLINE, PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials was conducted from January 10, 1966 to May 20, 2022. Randomized controlled trials and observational studies comparing the CCRT alone with CCRT plus ACT were included. The literature search, quality assessment, and data extraction were conducted by two reviewers independently. The primary endpoints were 3-year rates of overall survival (OS) and progression-free survival (PFS). Complete response rate, local recurrence, distant metastasis, and adverse events were secondary outcomes. The hazard ratios (HRs) and relative risk (RR) were pooled.ResultsNine studies with a total of 2732 patients were included in this meta-analysis, including 1411 patients in the CCRT group and 1321 in the CCRT plus ACT group. The HR for 3-year rates of OS and PFS of the CCRT group compared with the CCRT plus ACT group was 0.72 [95%confidence interval (CI) = 0.44–1.17] and 0.78 (95%CI = 0.5–1.75), respectively. No significant differences were observed between the two groups in the complete response rate (RR = 1.06, 95%CI = 0.96–1.16). However, local recurrence and distant metastasis were significantly lower in the CCRT plus ACT group than in the CCRT group (RR = 0.63, 95%CI = 0.44 –0.91 and RR = 0.64, 95%CI = 0.47–0.88). Grade 3–4 acute toxicities were more frequent in the CCRT plus ACT group (RR = 1.73, 95%CI =1.19–2.52).ConclusionAlthough associated with a decreased risk of local recurrence and distant metastasis, ACT did not significantly improve the survival rate and the complete response rate with increasing grade 3–4 acute toxicities in patients with LACC. Thus, this ACT regimen cannot be recommended for patients with LACC.Systematic review registrationhttps://inplasy.com/inplasy-2022-9-0089/, identifier INPLASY202290089.https://www.frontiersin.org/articles/10.3389/fonc.2022.997030/fullconcurrentchemoradiotherapyadjuvant chemotherapycervical cancermeta-analysis |
| spellingShingle | Haonan Liu Xiao Ma Chenyu Sun Meng Wu Zhiyuan Xu Shuang Zhou Nan Yao Suya Liu Xiaobing Qin Zhengxiang Han Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis Frontiers in Oncology concurrent chemoradiotherapy adjuvant chemotherapy cervical cancer meta-analysis |
| title | Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis |
| title_full | Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis |
| title_fullStr | Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis |
| title_full_unstemmed | Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis |
| title_short | Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis |
| title_sort | concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer a systematic review and meta analysis |
| topic | concurrent chemoradiotherapy adjuvant chemotherapy cervical cancer meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.997030/full |
| work_keys_str_mv | AT haonanliu concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT xiaoma concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT chenyusun concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT mengwu concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT zhiyuanxu concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT shuangzhou concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT nanyao concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT suyaliu concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT xiaobingqin concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis AT zhengxianghan concurrentchemoradiotherapyfollowedbyadjuvantchemotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedcervicalcancerasystematicreviewandmetaanalysis |